A clinical evaluation of the efficacy and tolerability of isradipine in the treatment of hypertension in a Chinese population
Publication in refereed journal


全文

其它資訊
摘要The efficacy and tolerability of isradipine (1.25 and 2.5 mg BID) were assessed in a placebo-controlled open trial in 50 Chinese subjects of varying ages (mean ± SD age 64 ± 11 years, range 40 - 79 years). Significant reductions in blood pressure were achieved with both dosages of isradipine, and the overall responder and normalization rates were 68% and 40%, respectively. No age-related changes in efficacy were demonstrated. There were no changes in hematological or biochemical parameters, chest x-ray, or electrocardiographic findings. The incidence of side effects was not different from that on placebo. These findings are similar to those reported in Caucasian subjects.
著者Woo J., Chan T.Y.K., Critchley J.A.J.H.
期刊名稱Advances in Therapy
出版年份1990
月份12
日期1
卷號7
期次6
出版社Health Communications, Inc.
出版地United States
頁次362 - 368
國際標準期刊號0741-238X
電子國際標準期刊號1865-8652
語言英式英語

上次更新時間 2021-13-10 於 23:21